We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We are delighted to share the release of our latest scientific paper outlining a drug delivery strategy poised to redefine cancer therapy.
Here's an overview of what we've uncovered:
Addressing treatment challenges: Current approaches to cancer treatment are limited by high general toxicity and low efficacy, driving a pressing need for novel, innovative treatment strategies.
Unlocking potential with combination therapy: Drawing inspiration from successful combination treatments in other medical fields, combination approaches could hold tremendous promise in enhancing treatment efficacy and overcoming resistance mechanisms.
Focusing on siRNA delivery: With small interfering RNA (siRNA) becoming increasingly used in the development of therapeutics, it is critical that these nucleic acids are delivered to tumours safely and efficiently. Dual delivery of siRNA, with or without a relevant, additional, small-molecule therapeutic agent, may be the key to unlocking a new era of treatment efficiency in cancer.
Innovative delivery platform: Departing from conventional delivery methods, mesoporous silica nanoparticles (MSNs) offer a potential solution for precise drug delivery. A novel silica nanoparticle delivery system has been developed (Nuvec®, N4 Pharma) specifically to safely and efficiently deliver siRNAs to tumours to inhibit multiple tumour growth factor pathway. Novel delivery systems that allow for double or even multiple siRNA loading will be critical to the success of future siRNA-based cancer therapeutics.
We believe this drug delivery approach provides a clear strategy to pave the way for more targeted and efficient first-line cancer therapy. A solid delivery platform will be pivotal in allowing developers to realise their goals.
2 x £1 buys
And a 50p sell !!!
We're up 3 % 🤣🤣
Any chance I can get me thousands back Nigel
It's hard to dispute that Vander. I think all of us LTH have some faith in the product or we wouldn't be here but i must admit my medical science knowledge is pretty much zero.
still hoping we haven't backed a donkey but i have only seen things get worse over the 5 years i have been invested.
fingers are still firmly crossed.
This is not gaining momentum or generating much excitement in the scientific community
To do so requires some academic endorsement through journal publications or conference presentations
Its stuck near the start line
It does say they will present to potential partners.
This is the news we need. It's another big step but it's not going to get the investors in.
Nigel must realize this. The next raise won't be funded by us it will be by these partners. Nigel already mentioned this.
The clock is ticking and it a very depressing to look at the price after the recent run. Were back where we started from.
Patents in all these countries don't mean a lot until we have something commercially viable.
What is going on here at N4P. Why is it the same update for years.
Avg arounf 4p here. Invested around £15k. I don't expect to see that anytime soon. It takes an age to do anything at N4P.
It’s good therapy to think out loud! Quite honestly treading water is his speciality. Yes it is virtually impossibly for life science to raise money if they have zero income. We don’t even have a product until they find a drug developer to utilise the theory. Bit of a catch 22 here.
Anyone might consider Nigel is just running the company as frugal as possible, making small advances without spending beyond his means? It’s pointless raising in this market, it’d dilute us far too much get anywhere near clinic.
I assume he’s treading water until it’s sufficiently viable to raise, could be a very wise strategic decision.
Only thinking out loud, don’t shoot.
Exactly my first thought Wully. Nige wants to know how likely I would be to recommending n4 to a
Friend as an investment. Nigel I want to keep my friends. How close are we to a deal? Then I’ll tell you if there was a dogs chance of recommending to a friend. Fully expect the market to pass on this non news. I don’t think Nige is as naive as he makes out which is a worry. On the other hand the nanogenics deal looks a blinder as long as this doesn’t turn into another endless university project. He doesn’t need to convince investors he needs to convince the market, then investors will come running
Yes it works !!! You keep telling us that ...
More tests , more tests , more tests!!!!
Get the big boys signed up ASAP. ....
Another red day on the cards 😴
Excellent to get dual loading update. 👍There should also be a short video update on the investor portal today.
Yes Nigel does respond to messages on the portal.
Nearly a month since the last RNS. it's so frustrating when the company don't communicate.
i understand they may have very little to say but when the SP is so low you would think they would be starting to put things in motion to garner interest before it tanks more.
has anyone used the portal they advertised? Are they responding to investors?
No idea who would sell at this level. But again this is being pushed down for another rinse and repeat.
Fortunately zero is the lowest it can go. October 2023 it went to .65p if people think it’s worth selling at this price it’s their 📞. Don’t see the point myself. A director bought a junk recently. We know they can can survive to prospective clinical trials for Nanogenics in 2025. We know at least three universities are conducting research for N4p. Quite why Nigel made so obvious he was testing the water for another possible raise at this stage I don’t know or for how much. Aside from all that there is the possibility of a partnership announcement . The trouble is, is that likely to happen pre clinical trials? The report was pretty emphatic about the advantages their drug delivery technology can make to the treatments of aggressive disease.
Lowest this share has Eva been !!!
The report was commissioned by N4P so no different than a paid-for broker note in essence. I do agree though it is a solid read and hopefully will help their external comms efforts in an attempt to attract a big pharma JV
Unfortunately the markets feel pretty strange right now. Very mixed signals. ‘A rapid rise out of mild recession’ ? Certainly a lot of volatility across the board. I have been in Melbourne for last two months where the economy is extremely buoyant, although property has cooled a little. I met someone from a life science company the other evening and they were very bullish about biotech, agreeing we are on the cusp of some massive advances in medicines . Feel quite a bit more hopeful with N4p but obviously still highly risky. Gl all.
It’s not the private investor that’s going to get this noticed. There are plenty of stocks that just don’t get the investors eye, especially at a time when money is sitting on the fence. What does amaze me is how little notice the medical and drug development industry seems to be taking. The competition just in nano tech is fierce and the big money is in USA. The dots do appear to be aligning slowly, mostly in university labs it would appear at the moment. A well established drug company is where the next big leap has to come from.
It's a great report. I just don't think we promote this enough.
Highly recommend looking at the EpiVax website. Whether this is report is a commission or endorsement it is the best piece of news I have read about N4p. It almost worries me that there has been so little reaction to it. Why anyone would sell now is also quite weird. Any way new hope for holders and cancer sufferers. They must succeed.
And so we edge nearer hopefully
At last some meaningful news. An email of a report that concludes that Nuvec could help the treatment of ‘refactory cancer’, a cancer that is resistant to either the beginning of conventional treatment or becomes resistant to repeated conventional treatments. The report should help progress towards clinical trials
Https://x.com/n4pharma/status/1750092298270941486?s=46&t=8sZkNZm7bOgIzay-ij0-gA
As happens with many companies listed on AIM, they lose 90 percent or more of their value from listing , especially when they have no revenue and continually rely on placings to stay afloat. The advantage of being listed was shown when N4p was able to raise funds to buy Nanogenics recently, who not being listed could not raise the money they needed to stay afloat. This provides opportunities for listed companies to add T bargain prices. Don’t k ow why Nigel feels the need to RNS every single patent news. It’s hardly price sensitive news and they have a website and now an investor hub. Price sensitive news is when they start making money or get a partner.